Onkure Therapeutics Inc. has described phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular ...

PI3Kα mutations are prevalent in patients with breast, colorectal, lung, endometrial, and numerous other cancers. However, the first-generation drugs targeting PI3Kα inhibit the wild-type and ...

Prelude Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and ...

SNV4818 is a potentially best-in-class pan-mutant-selective PI3Kα inhibitor that may effectively cover kinase (H), helical domain (E), and other PI3Kα mutations clinically. This marks the second ...

Scorpion's lead drug asset, a mutant-selective PI3Kα inhibitor known as STX-478, is currently in Phase 1/2 testing for the treatment of breast cancer and other solid tumors. Under the deal ...

BridgeBio Oncology Therapeutics, which is working on a pipeline of small-molecule therapeutics targeting RAS and PI3Kα malignancies, is planning to merge with publicly listed blank check company ...

The firm highlighted OnKure Therapeutics as a clinical-stage company focused on precision oncology, specifically developing targeted PI3Kα inhibitors for the treatment of breast cancer and other ...

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at ...

"We are thrilled to present the first clinical data for our lead program, OKI-219, which is the only highly selective PI3Kα H1047R inhibitor molecule in the clinic,” said Nicholas Saccomano, Ph.D., ...

tested hierarchically in patients with PI3Kα mutations in the kinase domain only and in patients with any PI3Kα mutation (kinase + non-kinase mutations) Overall survival is a key secondary ...

InitiationofPhase3ReDiscover-2trialofRLY-2608+fulvestrantanticipatedinthemiddleof2025in PI3Kα-mutated,CDK4/6pre-treated,HR+/HER2-metastaticbreastcancer ...